Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 4Lymphoid 2Other hematologic neoplasm 1Gynecologic 1Gastrointestinal 1Classical hematology 1CNS 1

Conditions

Lymphoma 666Lymphoma, Non-Hodgkin 593Leukemia, Lymphocytic, Chronic, B-Cell 535Precursor Cell Lymphoblastic Leukemia-Lymphoma 485Lymphoma, Follicular 418Lymphoma, Large B-Cell, Diffuse 379Leukemia 358Hodgkin Disease 354Lymphoma, Mantle-Cell 306Leukemia, Myeloid, Acute 250Multiple Myeloma 237Myelodysplastic Syndromes 214Lymphoma, B-Cell, Marginal Zone 196Recurrence 195Burkitt Lymphoma 189Waldenstrom Macroglobulinemia 155Leukemia, Myelogenous, Chronic, BCR-ABL Positive 130Lymphoma, B-Cell 127Neoplasms 118Lymphoma, T-Cell, Cutaneous 116Lymphoma, Large-Cell, Anaplastic 113Hematologic Neoplasms 103Lymphoma, Large-Cell, Immunoblastic 100Mycosis Fungoides 95Myeloproliferative Disorders 94Sezary Syndrome 86Lymphoma, T-Cell, Peripheral 83Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 81Lymphoma, T-Cell 74Primary Myelofibrosis 70

Interventions

Etoposide 2Cytarabine 2Cyclophosphamide 2sodium thiosulfate 1pegfilgrastim 1pegaspargase 1etoposide phosphate 1Vincristine 1Rituximab 1Radiotherapy 1Prednisolone 1Methylprednisolone 1Methotrexate 1Mercaptopurine 1Leucovorin 1Hydrocortisone 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Doxorubicin 1Dexrazoxane 1Dexamethasone 1Carboplatin 1Asparaginase 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Drug-Related Side Effects and Adverse Reactions × Lymphoid × Clear all
NCT00400946 2026-02-13

05-001: Treatment of Acute Lymphoblastic Leukemia in Children

Dana-Farber Cancer Institute

Phase 3 Completed
800 enrolled 22 charts
LymphoidOther hematologic neoplasm

Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Drug-Related Side Effects and Adverse Reactions

NCT00074165 2023-07-06

Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen

OHSU Knight Cancer Institute

Phase 2 Terminated
17 enrolled 7 charts
CNSClassical hematologyLymphoid

Lymphoma, Thrombocytopenia, Central Nervous System Neoplasms, Intraocular Lymphoma, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡